Cargando…

Matrix Metalloproteinase-8 Inhibitor Ameliorates Inflammatory Responses and Behavioral Deficits in LRRK2 G2019S Parkinson’s Disease Model Mice

Parkinson’s disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons in the substantia nigra (SN). Matrix metalloproteinases-8 (MMP-8), neutrophil collagenase, is a functional player in the progressive pathology of various inflammatory disorders. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Taewoo, Jeon, Jeha, Park, Jin-Sun, Park, Yeongwon, Kim, Jooeui, Noh, Haneul, Kim, Hee-Sun, Seo, Hyemyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Applied Pharmacology 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411029/ https://www.ncbi.nlm.nih.gov/pubmed/34045367 http://dx.doi.org/10.4062/biomolther.2020.181

Ejemplares similares

HDAC Inhibition by Valproic Acid Induces Neuroprotection and Improvement of PD-like Behaviors in LRRK2 R1441G Transgenic Mice
por: Kim, Taewoo, et al.
Publicado: (2019)

LRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25
por: Yun, Hye Jin, et al.
Publicado: (2013)

The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson's Disease and Multiple System Atrophy
por: Cho, Jin-Whan, et al.
Publicado: (2009)

Prediction of miRNA-mRNA associations in Alzheimer’s disease mice using network topology
por: Noh, Haneul, et al.
Publicado: (2014)

Age-associated chromatin relaxation is enhanced in Huntington's disease mice
por: Park, Myungsun, et al.
Publicado: (2017)

Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids
por: Kim, Hongwon, et al.
Publicado: (2019)

LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase
por: Choi, Insup, et al.
Publicado: (2015)

Increase in anti-apoptotic molecules, nucleolin, and heat shock protein 70, against upregulated LRRK2 kinase activity
por: Jang, Jihoon, et al.
Publicado: (2018)

Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression
por: Ho, Dong Hwan, et al.
Publicado: (2015)

Correction to: Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression
por: Ho, Dong Hwan, et al.
Publicado: (2017)

G2385R and I2020T Mutations Increase LRRK2 GTPase Activity
por: Ho, Dong Hwan, et al.
Publicado: (2016)

Brain cells derived from Alzheimer’s disease patients have multiple specific innate abnormalities in energy metabolism
por: Ryu, Woo-In, et al.
Publicado: (2021)

LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson’s disease
por: Rocha, Emily M., et al.
Publicado: (2019)

Quantitative Proteomic Analysis of Primitive Neural Stem Cells from LRRK2 G2019S-Associated Parkinson’s Disease Patient-Derived iPSCs
por: Sim, Hyuna, et al.
Publicado: (2020)

LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease
por: Galper, Jasmin, et al.
Publicado: (2022)

Amelioration of Pulmonary Fibrosis by Matrix Metalloproteinase-2 Overexpression
por: Inoue, Ryo, et al.
Publicado: (2023)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2017)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)

Matrix Metalloproteinases and Glaucoma
por: Kim, Moo Hyun, et al.
Publicado: (2022)

Effect of oleanolic acid on the activity, secretion and gene expression of matrix metalloproteinase-3 in articular chondrocytes in vitro and the production of matrix metalloproteinase-3 in vivo
por: Kang, Dong-Geun, et al.
Publicado: (2017)

Carnosine Protects against Cerebral Ischemic Injury by Inhibiting Matrix-Metalloproteinases
por: Kim, Eun-Hye, et al.
Publicado: (2021)

Correlation of matrix metalloproteinase 3 and matrix metalloproteinase 9 levels with non-motor symptoms in patients with Parkinson’s disease
por: Liu, Chuan Ze, et al.
Publicado: (2022)

Role of matrix metalloproteinase-9 in neurodevelopmental deficits and experience-dependent plasticity in Xenopus laevis
por: Gore, Sayali V, et al.
Publicado: (2021)

Models for LRRK2-Linked Parkinsonism
por: Li, Tianxia, et al.
Publicado: (2011)

The role of the LRRK2 gene in Parkinsonism
por: Li, Jie-Qiong, et al.
Publicado: (2014)

LRRK2 and Proteostasis in Parkinson’s Disease
por: Pérez-Carrión, María Dolores, et al.
Publicado: (2022)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor
por: Bright, Jessica M., et al.
Publicado: (2021)

Matrix Metalloproteinases in Cerebral Ischemia
por: Kim, Hahn Young, et al.
Publicado: (2006)

Correlation of expression and activity of matrix metalloproteinase-9 and -2 in human gingival cells of periodontitis patients
por: Kim, Kyung-A, et al.
Publicado: (2013)

Zingerone suppresses angiogenesis via inhibition of matrix metalloproteinases during tumor development
por: Bae, Woom-Yee, et al.
Publicado: (2016)

Ciliogenesis is Not Directly Regulated by LRRK2 Kinase Activity in Neurons
por: Kim, Hyejung, et al.
Publicado: (2021)

Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson’s disease treated with L-DOPA
por: Zhao, Ting Ting, et al.
Publicado: (2017)

Key Role of Microglial Matrix Metalloproteinases in Choroidal Neovascularization
por: Kim, Juhee, et al.
Publicado: (2021)

Eosinophil inflammation of nasal polyp tissue: relationships with matrix metalloproteinases, tissue inhibitor of metalloproteinase-1, and transforming growth factor-beta1.
por: Lee, Young-Mok, et al.
Publicado: (2003)

Nonmotor Symptoms in LRRK2 G2019S Associated Parkinson’s Disease
por: Gaig, Carles, et al.
Publicado: (2014)

Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease
por: San Luciano, Marta, et al.
Publicado: (2017)

Parkinson’s disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes
por: Lee, Jee Hoon, et al.
Publicado: (2019)

Overexpression of Parkinson’s Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology
por: Xiong, Yulan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rkccep8lo6364b98nb0iegqb44